Tested Applications
Positive FC detected in | human peripheral blood leukocytes |
Recommended dilution
Application | Dilution |
---|---|
Flow Cytometry (FC) | FC : 0.13 ug per 10^6 cells in 100 μl suspension |
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
98264-6-RR targets Siglec-9 in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen | Recombinant protein Predict reactive species |
Full Name | sialic acid binding Ig-like lectin 9 |
Calculated Molecular Weight | 50 kDa |
GenBank Accession Number | NM_014441.3 |
Gene Symbol | Siglec-9 |
Gene ID (NCBI) | 27180 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | Q9Y336-1 |
Storage Buffer | PBS with 0.09% sodium azide, pH 7.3. |
Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
Sialic acid binding Ig-like lectin 9 (Siglec-9), also known as CD329, is a member of the Siglec family of glycan-recognition proteins. Siglec-9 is a type-I transmembrane protein consisting of an N-terminal extracellular region that contains an N-terminal V-set domain and two C2-set domains, a transmembrane region, and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif (PMID: 10801862). It is expressed quite broadly among human blood leukocytes, including monocytes, neutrophils, B cells, NK cells, and minor subsets of T cells (PMID: 32322597). Siglec-9 functions as an inhibitory immune checkpoint and can be targeted to enhance therapeutic antitumor immunity (PMID: 34155121; 37460871).
Protocols
Product Specific Protocols | |
---|---|
FC protocol for Siglec-9 antibody 98264-6-RR | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |